Parametric Portfolio Associates LLC lowered its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 14.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,095 shares of the biotechnology company’s stock after selling 11,598 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Ironwood Pharmaceuticals were worth $1,305,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently modified their holdings of IRWD. Teacher Retirement System of Texas bought a new position in Ironwood Pharmaceuticals in the 2nd quarter worth about $192,000. Strs Ohio boosted its stake in Ironwood Pharmaceuticals by 63.1% in the 2nd quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 4,100 shares during the period. KCG Holdings Inc. boosted its stake in Ironwood Pharmaceuticals by 20.5% in the 1st quarter. KCG Holdings Inc. now owns 14,270 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 2,428 shares during the period. Aperio Group LLC boosted its stake in Ironwood Pharmaceuticals by 11.9% in the 2nd quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 1,410 shares during the period. Finally, Turner Investments LLC bought a new position in Ironwood Pharmaceuticals in the 2nd quarter worth about $302,000. Institutional investors and hedge funds own 98.83% of the company’s stock.
Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) opened at $14.93 on Wednesday. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. Ironwood Pharmaceuticals, Inc. has a 12-month low of $13.43 and a 12-month high of $19.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million during the quarter, compared to the consensus estimate of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The company’s revenue for the quarter was up 31.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.18) EPS. equities analysts predict that Ironwood Pharmaceuticals, Inc. will post -1.12 earnings per share for the current fiscal year.
IRWD has been the subject of several analyst reports. BidaskClub upgraded Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Wells Fargo & Company set a $19.00 target price on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, July 22nd. ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Mizuho restated a “buy” rating and issued a $23.00 target price (up previously from $22.00) on shares of Ironwood Pharmaceuticals in a research note on Wednesday, August 2nd. Finally, Wood & Company downgraded Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Friday, July 21st. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $18.29.
Ironwood Pharmaceuticals Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.